Fusion protein of cytokines and ferritin subunits, its preparation method and application
By fusing interferon with ferritin subunits and optimizing the design, the problem of insufficient expression and activity of interferon in the host was solved, and efficient and safe antiviral drug preparation was achieved.
Patent Information
- Application Number
- CN202311126420.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-01
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-09-01
AI Technical Summary
Current interferons used in clinical applications have small molecular weights and are easily cleared quickly, resulting in insufficient expression levels and activity, which limits their efficacy.
By fusing interferon with ferritin subunits to form a fusion protein, and through optimized design and amino acid mutation, the self-assembly properties of ferritin are utilized to display interferon on the surface of nanoparticles, thereby increasing expression levels and activity and prolonging half-life.
It significantly increased the expression and activity of interferon in the host, prolonged the half-life, enhanced the antiviral effect, and provided the possibility of safe, low-cost large-scale production.
Smart Images

Figure CN117327194B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to self-assembled ferritin nanoparticles, and more particularly to fusion proteins obtained by fusing cytokines and ferritin subunits, their preparation methods, and their applications in the preparation of antiviral drugs, belonging to the field of fusion proteins of cytokines and ferritin and their applications. Background Technology
[0002] Cytokines are a class of proteins or polypeptides that regulate cell proliferation and differentiation, and are important information transmission mediators in the body. Cytokines can be classified into interleukins, interferons, tumor necrosis factor superfamily, colony-stimulating factors, chemokines, growth factors, etc.
[0003] Interferons are a class of cytokines that were first discovered. They are active proteins with broad-spectrum antiviral functions on the same type of cells. Their activity is regulated and controlled by cellular genes and involves the synthesis of RNA and proteins. Based on differences in homology and receptor specificity, they are divided into three types of interferons: type I, type II and type III.
[0004] Type I interferons include IFN-α (more than a dozen subtypes have been discovered), IFN-β, IFN-κ, IFN-ω, and IFN-ε subtypes. All type I IFNs bind to heterodimeric receptors composed of two strands, IFNAR1 and IFNAR2, which signal by recruiting Janus-activated kinases (JAKs) TYK2 and JAK1, respectively. Activation of these JAKs leads to tyrosine phosphorylation of the signal transducers and transcription activators STAT1 and STAT2. Phosphorylated STAT1 and STAT2 dimerize and translocate to the nucleus, assembling with IRF9 to form interferon-stimulated gene factor 3 (ISGF3). Type I IFNs play roles in limiting infectious agents, regulating innate immune responses, activating the adaptive immune system, and anti-proliferation.
[0005] Type II interferons, with only one member, IFN-γ, also known as immune interferon, only exhibit good biological activity when present as a homodimer, making its expression a challenging aspect of genetic engineering. IFN-γ is an important cytokine in the body, coordinating the body's immune response by regulating the transcription of immune-related genes, promoting the processing and presentation of MHC class I and II antigens, and enhancing the body's immune surveillance function. Among interferons, only IFN-γ can effectively upregulate the presentation of MHC class II antigens. IFN-γ bridges the innate and acquired immune responses, coordinating the recognition of pathogens by innate immune cells and inducing specific immune responses, activating the microbial-killing function of macrophages, and promoting the production of inflammatory cytokines. IFN-γ primarily exerts its antiviral effect by binding to cell surface receptors, inducing the production of various antiviral proteins in virus-infected cells, thus creating an intracellular antiviral state. Furthermore, IFN-γ can also interfere with the cell cycle and inhibit cell proliferation.
[0006] Type III interferons exhibit similar biological activities, all possessing the intrinsic ability to induce antiviral activity in cells. Among the IFN-λs subtypes, IFN-λ1 and IFN-λ2 share 81% amino acid sequence homology, while IFN-λ2 and IFN-λ3 are virtually indistinguishable, sharing 96% amino acid sequence homology. IFN-λ4 shows less similarity to IFN-λ1-3, with only 30% amino acid sequence homology. All IFN-λs bind to the IFN-λ receptor complex, composed of a specific IFN-λR1 (IL28RA) and a shared IL-10R2 (IL-10Rβ), subsequently generating a JAK-STAT pathway response similar to that of type I interferons. The only difference is that IFN-λs can also utilize JAK2.
[0007] Interferon has become a research hotspot in virology, cell biology, molecular biology, clinical medicine, immunology, oncology, and other related fields due to its broad-spectrum antiviral and antitumor activities and potent immunomodulatory effects. However, its clinical efficacy is limited by its small molecular weight, which makes it easily and rapidly eliminated. Therefore, increasing the expression level and activity of interferon in the host, prolonging its in vitro and in vivo half-life, and obtaining safe and long-acting interferon are of great significance. Summary of the Invention
[0008] One of the objectives of this invention is to provide a fusion protein of cytokines and ferritin subunits. After expression, this fusion protein can be displayed on the surface of nanoparticles and form a conformation suitable for cytokines to perform their appropriate functions, effectively increasing the expression level and activity of cytokines in the host and prolonging the in vivo and in vitro half-life of cytokines.
[0009] A second objective of this invention is to provide a mutant of the fusion protein of the cytokine and ferritin subunit;
[0010] A third objective of this invention is to provide a method for preparing a fusion protein of cytokines and ferritin subunits or a mutant thereof;
[0011] The fourth objective of this invention is to apply the fusion protein of the cytokine and ferritin subunit, or its mutant, to the preparation of antiviral drugs.
[0012] To achieve the above objectives, the technical solution adopted by the present invention includes:
[0013] One aspect of the present invention is to provide a fusion protein of cytokines and ferritin subunits, wherein the fusion protein is obtained by linking the C-terminus of cytokines and monomeric ferritin subunits via a linker peptide.
[0014] The cytokines described in this invention include, but are not limited to, interleukins, interferons, tumor necrosis factor superfamily, colony-stimulating factors, chemokines or growth factors, with interferons being preferred.
[0015] In a preferred embodiment of the present invention, the interferon is preferably any one of human gamma-interferon, porcine α-interferon, or porcine λ-interferon; wherein, the original amino acid sequence of the human gamma-interferon is NP_000610.2 in NCBI GenBank, its amino acid sequence is shown in SEQ ID No. 1, and its encoding gene nucleotide sequence is shown in SEQ ID No. 2; the original amino acid sequence of the porcine α-interferon is ABB51633.1 in NCBI GenBank, its amino acid sequence is shown in SEQ ID No. 3, and its encoding gene nucleotide sequence is shown in SEQ ID No. 4; the original amino acid sequence of the porcine λ-interferon is XP_020953489.1 in NCBI GenBank, its amino acid sequence is shown in SEQ ID No. 5, and its encoding gene nucleotide sequence is shown in SEQ ID No. 6.
[0016] In a preferred embodiment of the present invention, the monomeric ferritin subunit includes any one of bacterial ferritin subunits, plant ferritin subunits, algal ferritin subunits, insect ferritin subunits, fungal ferritin subunits, or vertebrate ferritin subunits; more preferably, the monomeric ferritin subunit of the present invention is preferably a human ferritin heavy chain subunit or a porcine ferritin heavy chain subunit, wherein the original amino acid sequence of the human ferritin heavy chain subunit has the sequence number NP_002023.2 in GenBank on NCBI; and the original amino acid sequence of the porcine ferritin heavy chain subunit has the sequence number NP_999140.1 in GenBank on NCBI.
[0017] To facilitate its expression and form a conformation suitable for interferon to perform its function, this invention fuses human gamma-interferon and human ferritin subunits to obtain a fusion protein. The second to fifth amino acids of human ferritin are removed. To prevent the target protein from being encapsulated by ferritin, the last 21 amino acids of human ferritin are removed. This modification transforms the displayed protein conformation from a trilobal shape to a homodimer, which is beneficial for interferon function. A linker is attached to the C-terminus of the modified human ferritin subunit to obtain a fusion protein with the amino acid sequence shown in SEQ ID No. 7. The coding gene of the fusion protein shown in SEQ ID No. 7 is optimized to obtain the coding gene shown in SEQ ID No. 8. Furthermore, this invention fuses the fusion protein with the amino acid sequence shown in SEQ ID No. 7 with human gamma-interferon shown in SEQ ID No. 1 to obtain a fusion protein with the amino acid sequence shown in SEQ ID No. 11.
[0018] In this invention, when fusing porcine α-interferon and porcine ferritin subunits to obtain a fusion protein, the second to fourth amino acids of porcine ferritin are removed. To prevent the target protein from being encapsulated by ferritin, the last 20 amino acids of porcine ferritin are also removed. This modification transforms the displayed protein conformation from a trilobal shape to a homodimer, which is beneficial for the function of interferon. A linker is then attached to the C-terminus of the modified porcine ferritin subunit to obtain a fusion protein with the amino acid sequence shown in SEQ ID No. 9. The coding gene of the fusion protein shown in SEQ ID No. 9 is optimized to obtain the coding gene with the nucleotide sequence shown in SEQ ID No. 10. The fusion protein with the amino acid sequence shown in SEQ ID No. 9 is then fused with porcine α-interferon with the amino acid sequence shown in SEQ ID No. 3 to obtain a fusion protein with the amino acid sequence shown in SEQ No. 13.
[0019] When fusing porcine λ-interferon and porcine ferritin subunits to obtain the fusion protein, the 2nd to 4th amino acids of porcine ferritin were removed. To prevent the target protein from being encapsulated by ferritin, the last 20 amino acids of porcine ferritin were also removed. This modification changed the displayed protein conformation from a trilobal shape to a homodimer, which is beneficial for the function of interferon. A linker was attached to the end of the modified porcine ferritin subunit to obtain a protein with the amino acid sequence shown in SEQ ID No. 9. The fusion protein with the amino acid sequence shown in SEQ ID No. 9 was then fused with porcine λ-interferon with the amino acid sequence shown in SEQ ID No. 5 to obtain the fusion protein with the amino acid sequence shown in SEQ No. 15.
[0020] This invention further discovered that the expression levels and activities of the fusion protein obtained by linking cytokines to monomeric ferritin subunits were not ideal in the host during fusion expression. To improve the expression level of the fusion protein obtained by linking cytokines to monomeric ferritin subunits, this invention utilizes OptimumGene... TM Based on the codon biases of *E. coli* and *Bombyx mori*, this invention optimizes the nucleotide sequences encoding cytokines and fusion proteins. It optimizes various parameters affecting gene transcription efficiency, translation efficiency, and protein folding, including GC content, CpG dinucleotide content, codon bias, mRNA secondary structure, mRNA free energy stability, RNA instability gene sequences, and repetitive sequences, while maintaining the final translated protein sequence unchanged. The optimized nucleotide sequences obtained by optimizing the coding gene of the fusion protein shown in SEQ ID No. 11 are shown in SEQ ID No. 12; the optimized nucleotide sequences obtained by optimizing the coding gene of the fusion protein shown in SEQ ID No. 13 are shown in SEQ ID No. 14; and the optimized nucleotide sequences obtained by optimizing the coding gene of the fusion protein shown in SEQ ID No. 15 are shown in SEQ ID No. 16. After sequence optimization, this invention performs single-site and double-site mutations on the fusion proteins to increase their expression levels and prolong their half-life.
[0021] Therefore, another aspect of the present invention provides a unit point mutant of a fusion protein comprising interferon and ferritin subunits, comprising:
[0022] (1) The fusion protein with the amino acid sequence shown in SEQ ID No. 11 was subjected to a single point mutation; specifically, multiple single point mutants were obtained by single point mutation of any one of the amino acids shown in SEQ ID No. 11, namely L189V, E202T, K227R, K236R, L249P, K261R, K273R, E286G, N290T or K323R; the present invention found that the single point mutants obtained by single point mutation of any one of the amino acids shown in SEQ ID No. 11, namely, E202T, L249P, K273R or N290T, have significantly improved antiviral activity.
[0023] (2) The fusion protein with the amino acid sequence shown in SEQ ID No. 13 was used to obtain a single point mutant by any one of the amino acid single point mutation methods of L223P, N350T or K243R, and its antiviral activity was significantly improved.
[0024] (3) The fusion protein with the amino acid sequence shown in SEQ ID No. 15 was used to obtain a single point mutant by any one of the amino acid single point mutation methods of K215R, E266T or L320P, and its antiviral activity was significantly improved.
[0025] In this invention, the meaning of the "E202T" single point mutation refers to the mutation of glutamic acid at position 202 to threonine, and the meanings of the other single point mutations are deduced by analogy.
[0026] Another aspect of the present invention provides a multi-site mutant of a fusion protein comprising interferon and ferritin subunits, including:
[0027] (1) Multiple two-site mutants obtained by performing any one of the following two-site mutation methods on the fusion protein with the amino acid sequence shown in SEQ ID NO.11: E202T-L249P, E202T-K273R, E202T-N290T, L249P-K273R, L249P-N290T or K273R-N290T, wherein the mutants obtained by the two-site mutation of E202T-K273R or K273R-N290T are preferred;
[0028] (2) A two-site mutant obtained by L223P-N350T two-site mutation of the fusion protein with the amino acid sequence shown in SEQ ID NO.13;
[0029] (3) A two-site mutant was obtained by performing a K215R-L320P two-site mutation on the fusion protein with the amino acid sequence shown in SEQ ID NO.15.
[0030] The meaning of the "E202T-L249P" double-site mutation mentioned in this invention refers to the mutation of glutamic acid at position 202 to threonine and the simultaneous mutation of leucine at position 249 to proline. The meanings of other double-site mutations are deduced by analogy.
[0031] This invention expressed the above-mentioned single-site mutants or two-site mutants in the silkworm eukaryotic expression system. The expression results showed that the expression levels of the single-site mutant or multi-site mutant sequences were significantly increased compared with the original sequences.
[0032] This invention utilizes Escherichia coli and eukaryotic baculovirus expression systems to express optimized ferritin self-assembled fusion proteins. The antiviral activity of these proteins is significantly higher than that of interferon expressed alone, with a serum half-life extended by several tens of times, demonstrating the advantage of ferritin displaying a polymeric surface. Furthermore, compared to ferritin fusion proteins expressed in E. coli, the fusion protein expressed using the baculovirus expression system exhibits significantly higher antiviral activity, showcasing the advantages of natural exogenous proteins.
[0033] Another aspect of the present invention provides a method for preparing a fusion protein of said interferon and ferritin subunit or a mutant thereof, comprising:
[0034] (1) Construct a prokaryotic or eukaryotic expression vector for the encoding gene of the fusion protein of interferon and ferritin subunit or its mutant; (2) Transform the constructed prokaryotic or eukaryotic expression vector into the corresponding host cell, express the fusion protein in the host cell, purify and renature it to obtain the protein.
[0035] Preferably, the encoding gene of the fusion protein of interferon and ferritin subunit or its mutant is cloned into a baculovirus transfer vector to construct a recombinant transfer vector; the recombinant transfer vector is co-transfected with baculovirus DNA into insect cells to obtain recombinant baculovirus; the recombinant baculovirus is used to infect insect hosts or cells, and the infected insect cells or insect hosts are cultured to express the corresponding interferon, and then purified to obtain the final product.
[0036] The fusion proteins or mutants of fusion proteins provided by this invention are protein components that are naturally present in animals. Therefore, they have low toxicity to animals, weak antigenicity, and long half-life. They can be used to prepare a variety of drugs for the prevention or treatment of viral infections, tumors, immune system diseases, and immune adjuvants. Their small molecular weight and high stability broaden their administration routes, which may include various routes such as intravenous injection, subcutaneous injection, and oral administration.
[0037] The interferon provided by this invention has a simple structure, small molecular weight, strong permeability, high stability, and weak antigenicity. Linking it to the C-terminus of the ferritin subunit can increase its stability in vivo and prolong its serum metabolic half-life.
[0038] This invention fuses interferon with the C-terminus of human or corresponding species of ferritin heavy chain via a linker to obtain a fusion protein, which is then expressed in prokaryotes or eukaryotes. The expressed fusion protein is displayed on the surface of nanoparticles and forms a conformation suitable for interferon to perform its appropriate function, effectively increasing the expression level and activity of interferon in the host and prolonging the in vivo and in vitro half-life of interferon.
[0039] Compared with the prior art, the present invention has the following advantages and effects:
[0040] 1. This invention utilizes the prokaryotic expression system Escherichia coli and the eukaryotic baculovirus expression system to express the cytokine-ferritin fusion protein. The preparation process does not involve live harmful viruses, making it safer, simpler, lower in cost, and suitable for rapid large-scale production compared to traditional antibody production methods.
[0041] 2. The interferon expressed in this invention has strong affinity, strong permeability, weak immunogenicity, and high stability. Its relatively simple structure also makes it easier to recombine and express. Its small molecular weight and high stability broaden its administration routes, allowing it to be administered via intravenous injection, subcutaneous injection, or oral administration.
[0042] 3. This invention fuses interferon with ferritin, utilizing the self-assembly properties of ferritin to display interferon on its surface. This enhances the affinity of interferon and significantly prolongs its half-life in vivo, resulting in better pharmaceutical efficacy. The baculovirus expression system possesses post-translational modification capabilities, allowing for the maximum utilization of the function of ferritin nanocages in displaying polymers.
[0043] Definitions of terms involved in this invention
[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0045] The term "interferon" (IFN) refers to an important class of cytokines whose activity is regulated and controlled by the cellular genome, involving the synthesis of RNA and proteins. The IFN protein family is classified into type I, type II, and type III interferons based on the sequence of their encoding genes, chromosomal location, and receptor specificity.
[0046] The term "recombinant protein" refers to proteins produced using recombinant DNA technology, which can be used to clone and express genes in a variety of hosts, including bacteria, mammalian cells, insect cells, and plants, to produce proteins.
[0047] The terms “mutation” and “mutant” have their common meanings here, referring to genetic, naturally occurring or introduced changes in a nucleic acid or polypeptide sequence, and their meanings are the same as those commonly known to those skilled in the art.
[0048] The terms "host cell" or "recombinant host cell" refer to a cell containing the polynucleotides of the present invention, regardless of the method used for insertion to produce a recombinant host cell, such as direct uptake, transduction, f-pairing, or other methods known in the art. The exogenous polynucleotides may remain as, for example, non-integrating vectors of plasmids or may be integrated into the host genome.
[0049] The term "transfection" refers to the process by which eukaryotic cells acquire new genetic markers due to the incorporation of foreign DNA. Attached Figure Description
[0050] Figure 1The spatial conformation and high-order structure prediction of the Ferritin-IFN-γ fusion protein clearly show that the protein structure is a homodimer.
[0051] Figure 2 Green fluorescence of Ferritin-IFN-γ expressed in E. coli inhibiting VSV virus replication; where A: fluorescence of the control group infected with VSV-GFP virus; B: fluorescence of VSV-GFP virus inhibited by γ-interferon; C: fluorescence of VSV-GFP virus inhibited by Ferritin-IFN-γ fusion protein expressed in E. coli.
[0052] Figure 3 Transmission electron microscopy (TEM) images of the purified and refolded Ferritin-IFN-γ E. coli expression product. A: Negative staining; B: Immunogold labeling, showing spherical structures of the expected size, with gold particles from the immunogold labeling using anti-ferritin heavy chain antibody as the primary antibody attached to the core of the spherical structures, indicating successful refolding of the fusion protein into spherical nanoparticles and displaying IFN-γ on the ferritin surface; C: Immunogold labeling, using human hIFN-γ antibody as the primary antibody, showing gold-labeled particles around the spherical structures, further confirming that hIFN-γ is displayed on the surface of the nanoparticles.
[0053] Figure 4 Analysis of drug metabolism in mice after intravenous injection of purified and refolded Ferritin-IFN-γ expression product in Escherichia coli;
[0054] Figure 5 The image shows the green fluorescence of the eukaryotic expression product Ferritin-IFN-γ inhibiting VSV virus replication; where A: fluorescence of the control group infected with VSV-GFP virus; B: fluorescence of VSV-GFP virus inhibited by γ-interferon; C: fluorescence of VSV-GFP virus inhibited by the Ferritin-IFN-γ fusion protein expressed in the silkworm system.
[0055] Figure 6 The images show transmission electron microscopy (TEM) images of the purified Ferritin-IFN-γ expression product from the silkworm system. A: negative staining; B: immunogold labeling, showing spherical structures of the expected size, with gold particles from the immunogold labeling using anti-ferritin heavy chain antibody as the primary antibody attached to the core of the spherical structures, indicating that the fusion protein is a spherical nanoparticle and that IFN-γ is displayed on the ferritin surface; C: immunogold labeling, using human hIFN-γ antibody as the primary antibody, showing gold-labeled particles around the spherical structures, further confirming that hIFN-γ is displayed on the surface of the nanoparticles.
[0056] Figure 7Analysis of drug metabolism in mouse serum after purification of the Ferritin-IFN-γ silkworm system expression product, where A: intravenous injection; B: oral gavage. Detailed Implementation
[0057] The present invention will be further described below with reference to specific embodiments, and the advantages and features of the present invention will become clearer with the description. However, it should be understood that the embodiments described are merely exemplary and do not constitute any limitation on the scope of the present invention. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solutions of the present invention without departing from the spirit and scope of the present invention, but such modifications or substitutions all fall within the protection scope of the present invention.
[0058] 1. Experimental materials and reagents
[0059] (1) Strains, viruses, and vectors: Prokaryotic expression vector pET-28a(+), transfer vector pBR, Escherichia coli competent cells Trans5α and Rosetta(DE3) were purchased from Beijing TransGen Biotechnology Co., Ltd., and silkworm cells BmN, Vero cells, and parental virus BmBacmid were preserved and provided by the Institute of Biotechnology, Chinese Academy of Agricultural Sciences. The experimental silkworm variety JY1 was provided by the Sericulture Research Institute of Jiangsu University of Science and Technology.
[0060] (2) Ferritin and interferon sequences: The optimized gene sequences were sent to GenScript for synthesis and cloned into the prokaryotic expression vector pUC57.
[0061] (3) Enzymes and reagents: Restriction endonucleases and T4 DNA ligase were purchased from Promega, LATaq DNA polymerase and other related reagents used in PCR were purchased from TakaRa, liposomes were purchased from Invitrogen, and DMEM cell culture medium and fetal bovine serum were products of GIBCO. The preparation methods for solutions and culture media were based on relevant reference books (Josephetal., Molecular Cloning: A Laboratory Manual, 3rd Edition, 2002; Osber et al., A Concise Guide to Molecular Biology, 1998; David L. Spector, A Guide to Cellular Experimentation, 2001); unless otherwise stated, percentages and parts are by weight.
[0062] The antibodies used in this experiment, such as the human ferritin heavy chain antibody, were purchased from Wuhan Aibotek Biotechnology Co., Ltd.; the human interferon antibody was purchased from Abcam.
[0063] 2. Fusion PCR method used for site-directed mutagenesis in the experimental methods.
[0064] The procedure was performed in accordance with the method described by Kuang Feiting et al. (A Novel Method for Vector Construction: Recombinant Fusion PCR, Genomics and Applied Biology, 2012, Vol. 31, No. 6, pp. 634-639).
[0065] 3. Preparation of solutions and culture media
[0066] For instructions on preparing solutions and culture media, please refer to relevant reference books (Joseph et al., Molecular Cloning: A Laboratory Manual, 3rd Edition, 2002; Osber et al., A Concise Guide to Molecular Biology, 1998).
[0067] 4. Synthesis of three interferon gene sequences and corresponding ferritin gene sequences.
[0068] The amino acid sequence of human gamma interferon is shown in SEQ ID NO.1, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.2. The amino acid sequence of the fusion protein obtained by linking human gamma interferon with the C-terminus of the human ferritin heavy chain subunit (with the 2nd to 5th amino acids removed and the last 21 amino acids removed) through 3×G3S is shown in SEQ ID NO.11, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.12.
[0069] The amino acid sequence of porcine α-interferon is shown in SEQ ID NO.3, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.4. The amino acid sequence of the fusion protein obtained by linking porcine α-interferon with the C-terminus of the porcine ferritin heavy chain subunit (with the 2nd to 5th amino acids removed and the last 21 amino acids removed) through 3×G3S is shown in SEQ ID NO.13, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.14.
[0070] The amino acid sequence of porcine λ-interferon is shown in SEQ ID NO.5, the nucleotide sequence of its encoding gene is shown in SEQ ID NO.6, and the amino acid sequence of the fusion protein obtained by linking porcine λ-interferon with the C-terminus of the porcine ferritin heavy chain subunit (with the 2nd to 5th amino acids removed and the last 21 amino acids removed) via 3×G3S is shown in SEQ ID NO.15.
[0071] Using OptimumGene TMBased on the codon preferences of *E. coli* and *Bombyx mori*, the nucleotide sequence was optimized. This optimization addressed various parameters affecting gene transcription efficiency, translation efficiency, and protein folding, including GC content, CpG dinucleotide content, codon preference, mRNA secondary structure, mRNA free energy stability, RNA instability gene sequences, and repetitive sequences, while maintaining the final translated protein sequence unchanged. The optimized nucleotide sequences obtained by optimizing the coding gene of the fusion protein shown in SEQ No. 11 (SEQ No. 12), the fusion protein shown in SEQ No. 13 (SEQ No. 14), and the fusion protein shown in SEQ No. 15 (SEQ No. 16) were then used to artificially synthesize the optimized interferon and ferritin fusion protein gene sequences.
[0072] 5. Construction of three recombinant plasmids pET28a-IFN and pET28a-Fe-IFN
[0073] 5.1 PCR amplification of three gene sequences and three fusion protein gene sequences
[0074] PCR amplification of three gene sequences:
[0075] IFN-γ
[0076] F 5'-CGGGATCCATGAAATACACCAGCTACATCC-3' R 5'-CGGAATTCTCACTGAGAGGCCCGTCTGC-3'
[0077] PIFN-ɑ
[0078] F 5'-CGGGATCCATGGCCCCGACCTCCGCTTTTC-3' R 5'-CGGAATTCTTATTCCTTCTTTCTGAGTCTG-3'
[0079] PIFN-λ
[0080] F 5'-CGGGATCCATGGCTCTGGGTGGTTCACTGG-3' R 5'-CGGAATTCTTAAACACACAGGTCACCTG-3'
[0081] Three gene sequences were amplified by PCR: Taking Fe-IFN-γ as an example, primers were designed, and pET28a-Fe-D4 was used as a template to obtain the Fe-linker nucleotide sequence by PCR. The Fe-linker was then linked to IFN-γ by fusion PCR.
[0082] F1 5'-CGGGATCCGCCAACATGACCAGCCAAGTGCGTCAA-3' R1 5'-GCTGGTGTATTTGCTGCCACCGCCGCTACC-3' F2 5'-CGGTGGCAGCAAATACACCAGCTACATCCTGGCC-3' R2 5'-CGGAATTCTCACTGAGAGGCCCGTCTGC-3'
[0083] Similarly, the fusion PCR primers for Fe-PIFN-α and Fe-PIFN-λ are shown below.
[0084] Fe-PIFN-ɑ
[0085] F1 5'-CGGGATCCGCCAACATGTGCAG-3' R1 5'-AGAAAAGCGGAGGTCGGGGCGCTGCCACCGCCGCTACC-3' F2 5'-GTGGTAGCGGCGGTGGCAGCGCCCCGACCTCCGCTTTTC-3' R2 5'-CGGAATTCTTATTCCTTCTTCTGAG-3'
[0086] Fe-PIFN-λ
[0087]
[0088]
[0089] The PCR reaction system is as follows: 1 μL template, 5 μL 10×LA Buffer, 1 μL dNTP Mix, 2 μL each of forward and reverse primers, 25 μL 2×Phanta Mix Buffer, 18 μL dd H2O, for a total volume of 50 μL.
[0090] PCR parameters were set as follows: 95℃, 30s; 95℃, 15s, 64℃, 15s, 72℃, 60s, for a total of 29 cycles; 72℃, 5min.
[0091] 5.2 Recovery of PCR Products
[0092] The PCR products were subjected to agarose gel electrophoresis. The target band was cut out under UV light and placed in an EP tube. Three volumes of 6M sodium iodide were added and the tube was thawed in a 55°C water bath. 8 μL of glass milk was added, mixed, and incubated on ice for 10 min, shaking every three minutes. The tube was centrifuged at 12000 rpm for 10 s and the supernatant was discarded. 800 μL of New Wash was added and the tube was gently washed, repeated three times. The supernatant was discarded, and the tube was dried in a 37°C oven for 5 min. 20 μL of 0.1×TE was added, mixed, and centrifuged at 12000 rpm for 5 min. The supernatant was collected and stored at -20°C.
[0093] 5.3 Enzyme digestion treatment of target gene PCR products
[0094] The PCR products were run on a gel, and the correctly recovered products were double-digested with restriction endonucleases BamHI and EcoRI to obtain the target fragment. The digestion system is as follows: 10 μL target fragment, 5 μL 10×Buffer E, 1 μL BamHI, 1 μL EcoRI, 33 μL ddH2O, total 50 μL.
[0095] 5.4 Ligation and transformation of the target gene with pET-28a(+) and pBR vectors
[0096] 5.4.1 Enzyme digestion
[0097] The pET-28a(+) vector and pBR vector were double-digested with restriction endonucleases BamHⅠ and EcoRI, inactivated at 85℃ for 10 min, and stored at -20℃ for later use.
[0098] 5.4.2 Connection
[0099] The target fragment recovered from enzyme digestion was ligated into the pET-28a(+) and pBR vectors that had been double-digested with BamHI / EcoRI. Ligation was performed using T4 DNA ligase at 25°C for 10 min. The ligation system was as follows: 6 μL of recovered target fragment, 1 μL of vector, 2 μL of 5×Buffer, and 5 μL of T4 DNA ligase, for a total of 10 μL.
[0100] 5.4.3 Transformation
[0101] Take competent cells stored at -80℃, thaw half of them quickly, add the above ligation product, and place on ice for half an hour; place in a 42℃ water bath for 90 seconds, then quickly place on ice for 3-5 minutes; add an appropriate amount of 2×YT medium to the tube, and incubate statically at 37℃ for 60 minutes; centrifuge, discard most of the supernatant, and keep 200 μL. Spread the ligation products of the target protein with pET-28a(+) and pBR on 2×YT plates (50 μg / mL Kana) and 2×YT plates (60 μg / mL Amp), respectively, and incubate upright at 37℃ for 30 minutes, then invert and incubate overnight.
[0102] 5.4.4 Initial screening of positive clones
[0103] Single colonies were picked from 2×YT plates and inoculated into 2×YT (50 μg / mL Kana) and 2×YT (60 μg / mL Amp) liquid media, respectively. The media were incubated overnight in a 37°C constant-temperature shaking incubator at 220 rpm. 500 μL of the bacterial culture was collected in a centrifuge tube. 30 μL of loading buffer and 20 μL of phenol / chloroform (1:1) were added, and the mixture was thoroughly vortexed to resuspend the bacterial cells. The cells were centrifuged at 12000 rpm for 3 min, and 8 μL of the supernatant was used for agarose gel electrophoresis. An empty vector treated in the same way was used as a control. The bands were observed under UV light using a gel imaging system. Plasmids were extracted from bacterial cultures where the plasmid band was significantly faded.
[0104] 5.4.5 Plasmid extraction by alkaline lysis method
[0105] The selected bacterial culture was centrifuged at 8000 rpm for 60 min, and the bacterial cells were collected in a 1.5 mL EP tube. The supernatant was discarded. 150 μL of Solution I was added, mixed with the bacterial cells, and incubated on ice for 5 min. 50 μL of Solution II and 50 μL of chloroform were added, mixed gently, and incubated on ice for 5 min. 450 μL of Solution III was added, mixed vigorously, and incubated on ice for 10 min. The mixture was then centrifuged at 12000 rpm at 4°C for 10 min. The supernatant was transferred to a clean EP tube, 500 μL of isopropanol was added, mixed thoroughly, and incubated on ice for 15 min. After incubating on ice, the mixture was centrifuged at 12000 rpm at 4°C for 10 min. The supernatant was discarded, and 250 μL of isopropanol was added. Incubate at TER at 37℃ for 20 min; add 300 μL PPT, mix thoroughly, incubate on ice for 25 min, then centrifuge at 12000 r / min, 4℃ for 10 min, and discard the supernatant; add 800 μL of ice-cold ethanol, wash the precipitate thoroughly, centrifuge at 12000 r / min, 4℃ for 10 min, and discard the supernatant. Repeat this operation twice, incubating at 37℃ for 20 min each time. After drying, add 50 μL of 0.1×TE to fully dissolve the precipitate and store at -20℃.
[0106] 5.4.6 Identification of positive clones by restriction enzyme digestion and sequencing
[0107] The enzyme digestion system is as follows: 3 μL recombinant plasmid DNA, 3 μL 10×Buffer E, 0.5 μL BamHI, 0.5 μL EcoRI, 14 μL ddH2O, totaling 20 μL. After incubation at 37℃ for 2 h, 7 μL was taken and analyzed by electrophoresis with 1% agarose gel. Sequencing of plasmid DNA that was correctly digested showed results consistent with the target gene.
[0108] Example 1: Prediction and analysis of the higher-order structure of the fusion of three interferons and their corresponding ferritins.
[0109] Analysis of the higher-order structure of the native cage-like structure of ferritin protein revealed that its C-terminus is an alpha helix of approximately 20 amino acids extending inward from the surface of the ferritin cage-like structure. Deleting this alpha helix exposes the C-terminal amino acid residues outside the ferritin cage-like structure, and the spatial proximity of the C-terminal residues among the four subunits, with six such sites on the cage-like structure surface, facilitates the formation of double-stranded structures during interferon-gamma expression. The fusion of four spatially close residues allows the expressed interferon-gamma single strands to bind in a random, adjacent manner. To further confirm the feasibility of this ferritin protein sequence design, its sequence was deployed on a local supercomputer and analyzed using AlphaFold 2 software with deep learning capabilities. Taking human ferritin as an example, the higher-order structure prediction is as follows: Figure 1As shown in the figure. The results show that removing 5 amino acids from the N-terminus and 21 amino acids from the C-terminus of the Ferritin protein ensures that the basic spatial backbone structure is consistent with the complete sequence. It is predicted to form a cage-like structure similar to the natural 24-mer, with the C-terminal residues exposed on the surface of the cage-like structure. The C-terminal residues of each pair of subunits are spatially close, which is conducive to the formation of homodimers. To further ensure the formation of interferon homodimers, a 3×G3S flexible linker peptide was added between the interferon and Ferritin sequences. The structure was predicted and analyzed using AlphaFold 2. The results show that the Ferritin structure is partially consistent with the natural structure and is predicted to form a natural 24-mer, which is the expected optimal 2×12 homodimer form. The flexible linker peptides are closely exposed on the outside of the ferritin nanocage structure, consistent with expectations. To improve the translation initiation efficiency of the target gene in the baculovirus eukaryotic expression system, the Kozak sequence GCCAAC was added before the gene. To improve the translation termination efficiency, the start codon ATG was added, and the stop codon was changed to TGA. In addition, BamHI was added upstream of the gene and EcoRI restriction enzyme site was added downstream of the gene to facilitate subsequent cloning into the eukaryotic transfer vector pBR and the prokaryotic expression vector pET-28a(+).
[0110] Experiment Example 2: Expression and Activity Determination of Fusion Proteins of Three Types of Interferon and Corresponding Ferritin in Escherichia coli 1. Experimental Methods
[0111] 1.1 Expression of fusion proteins of three types of interferon and their corresponding ferritin in Escherichia coli
[0112] The recombinant plasmids pET28a-IFN-γ, pET28a-Fe-IFN-γ, pET28a-PIFN-α, pET28a-Fe-IFN-α, pET28a-IFN-λ, and pET28a-Fe-PIFN-λ of the three correct interferon types were transformed into the Escherichia coli expression strain Rosetta(DE3), and 1 mL of 2×YT liquid medium was added and cultured at 37°C for 1 h.
[0113] Centrifuge the bacterial culture at 8000 rpm for 1 min, resuspend the bacterial cells in 200 μL of supernatant, and evenly spread the supernatant onto 2×YT solid plates (50 μg / mL, Kana). Incubate at 37°C for 30 min, then invert the plates overnight. Pick a single colony from the plate and add 4.5 mL of 2×YT liquid medium (50 μL / mL, Kana). Incubate at 37°C for 12 h at 220 rpm. After 12 h, transfer the colony to 4.5 mL of 2×YT medium (50 μg / mL, Kana) at a 1:100 ratio and continue incubating at 37°C for 200 rpm until the OD600 reaches 0.6-0.8. Then add different concentrations of IPTG (0.1 mM, 0.3 mM, 0.5 mM, 0.8 mM, 1.0 mM) and continue incubating for 5 h. Collect the bacterial cells by centrifugation at 8000 rpm for 10 min. The protein was broken down, and the supernatant and precipitate were collected separately for SDS-PAGE analysis to identify protein expression. The size of the recombinant protein was consistent with the expected size, indicating that the fusion protein was successfully expressed in E. coli.
[0114] 1.2 Western blot validation of recombinant proteins
[0115] To confirm the recombinant proteins obtained in the above experiments, Western blot verification was performed on the corresponding recombinant proteins of the three interferon types. The protein precipitates obtained from the above-mentioned fragmentation and centrifugation were subjected to SDS-PAGE electrophoresis. After electrophoresis, the gel was gently removed, the stacking gel was discarded, and the proteins were transferred to a nitrocellulose membrane using a wet transfer method. After transfer, the membrane was removed with tweezers, and PBST was added to cover the nitrocellulose membrane. The membrane was washed on a low-speed shaker for 10 min, repeated 3 times. After washing, 5% skim milk powder prepared with PBST was added, and the membrane was blocked on a low-speed shaker at room temperature for 3 h. After blocking, the membrane was washed with PBST for 10 min, repeated 3 times. Mouse His-tag primary antibody diluted 3000-fold was added, and the membrane was incubated on a low-speed shaker for 2 h. After His-tag primary antibody incubation, the membrane was washed 3 times with PBST, and HPR-labeled goat anti-mouse IgG secondary antibody diluted 6000-fold was added, and the membrane was incubated on a shaker for 2 h. After incubation, wash three times with PBST for 10 minutes each time, add chromogenic solution, and image and photograph in a fluorescence and chemiluminescence analyzer.
[0116] 1.3 High-level expression of recombinant proteins
[0117] Strains with high protein expression levels were removed from the -80℃ freezer, streaked onto plates, and incubated at 37℃ for 10 h. Single colonies were then picked and inoculated into 4.5 mL of 2×YT medium (50 μg / mL, Kana), and incubated at 37℃ and 220 rpm for 12 h. After 12 hours, the bacterial cells were inoculated at a ratio of 1:100 into 200 mL of medium (50 μg / mL, Kana), and incubated at 37℃ and 220 rpm until the OD600 was between 0.6 and 0.8. IPTG was then added to a final concentration of 1.0 mmol / L, and the culture was continued for another 5 h. After the culture was completed, the cells were centrifuged at 12000 rpm for 5 min, collected, and resuspended in PBS for washing. This process was repeated twice. After washing, the cells were resuspended in 20 mL of washing buffer, incubated on ice for 30 min, sonicated, and the precipitate was collected after centrifugation.
[0118] 1.4 Purification of recombinant proteins by nickel column affinity chromatography
[0119] The precipitate was resuspended in denaturing lysis buffer and stirred overnight at 4°C to ensure complete dissolution. The mixture was then centrifuged at 12000 rpm for 20 min at 4°C. The supernatant was collected and filtered through a 0.45 μm filter membrane for later use. The protein was eluted with 5 column volumes of elution buffer containing 250 mmol / L imidazole, and the eluted target protein was collected. After elution, the nickel column was washed with 50 mmol / L EDTA, ddH₂O, 0.5 mol / L NaOH, and ddH₂O, respectively. The column was then stored at 4°C with 5 column volumes of 25% ethanol. The purification results of the recombinant protein were analyzed by SDS-PAGE.
[0120] 1.5 Fusion Protein Dialysis Refolding and Ultrafiltration Concentration
[0121] The purified recombinant protein was diluted to a concentration of 150 μg / mL with denaturing elution buffer (without imidazole) and then placed in a dialysis bag. The dialysis bag should first be boiled in 2% (w / v) NaHCO3 and 1 mmol / L EDTA-2Na (pH=8.0) for 10 min, rinsed with ddH2O, and then boiled again in 1 mmol / L EDTA-2Na (pH=8.0) for 10 min.
[0122] After sealing the dialysis bag containing the protein with a clip, the urea concentration in the dialysate (containing an appropriate concentration of iron ions) was successively reduced to 6 mmol / L, 4 mmol / L, 2 mmol / L, 1 mmol / L, and 0 mmol / L. Each dialysate was placed in a constant temperature environment at 4°C and dialyzed at low speed with stirring. The dialysate of different concentrations was changed every 5 hours. Finally, filtered PBS was added, and the mixture was placed in a constant temperature environment at 4°C and dialyzed at low speed overnight with stirring. After centrifugation, the supernatant was collected for the next experiment.
[0123] 1.6 Electron Microscopy Observation
[0124] Taking Fe-IFN-γ as an example, after the protein sample purified by ultrafiltration or ultrafiltration is diluted 10 times, it is dropped onto a clean plastic film. The sample is carefully picked up by the edge of the copper mesh with pointed tweezers and adsorbed for 3 minutes. The excess sample is then adsorbed with filter paper, washed 3 times with ddH2O, and 1% uranium acetate staining solution is added. The sample is stained for 3 minutes, the excess staining solution is removed, and the sample is dried. The sample is then observed under a transmission electron microscope.
[0125] After ultrapurification, the protein sample was diluted 10-fold and dropped onto a clean plastic film. Using pointed tweezers, the edge of the copper mesh was carefully picked up to collect the sample. After 5 minutes of adsorption, excess sample was absorbed with filter paper. The sample was washed three times with ddH2O and then dried. Next, a 50-fold diluted rabbit ferritin primary antibody was dropped onto a clean plastic film. Using pointed tweezers, the edge of the copper mesh adsorbing Fe-IFN-γ protein was carefully picked up to collect the primary antibody. After incubation for 10 minutes, excess sample was absorbed with filter paper. The sample was washed three times with ddH2O and then dried. Finally, a 50-fold diluted goat anti-rabbit IgG gold-labeled secondary antibody was dropped onto a clean plastic film. Using pointed tweezers, the edge of the copper mesh was carefully picked up to collect the secondary antibody. After incubation for 10 minutes, excess sample was absorbed with filter paper. The sample was washed three times with ddH2O and then dried. A 1% uranium acetate staining solution was added, and staining was performed for 5 minutes. Excess staining was absorbed with filter paper, and the sample was air-dried for transmission electron microscopy observation. Similarly, porcine α and λ interferon were processed with the corresponding ferritin fusion proteins using the same method and observed by transmission electron microscopy.
[0126] 1.7 Detection of the antiviral activity of fusion proteins of three types of interferon and their corresponding ferritin
[0127] Taking the detection of the antiviral activity of IFN-γ and Ferritin-IFN-γ fusion protein as an example, the antiviral activity of γ-interferon and Ferritin-IFN-γ fusion protein expressed in E. coli was detected using the microcytopathic effect inhibition method on the Vero / VSV*GFP system, with pharmaceutical-grade interferon as the standard. Healthy Vero cells were seeded at a density of 3.0 × 10⁵ cells / mL in 96-well culture plates. Concentrated Ferritin-IFN-γ fusion protein and an equal volume of γ-interferon were prepared into solutions of different dilutions using DMEM culture medium containing 70 mL / L fetal bovine serum. The diluted samples were seeded at 100 μL / well into wells already confluent with Vero cells. At least 12 replicates were set up for each dilution and control protein solution. A cell control group without protein solution and VSV*GFP and a virus control group with VSV*GFP were also included. The cells were cultured at 37℃ and 5% CO₂ for 18–24 h. The culture was then diluted to 100 TCID⁻¹. 50VSV*GFP virus was added at 100 μL / well to culture wells after the supernatant had been aspirated, and incubated at 37°C and 5% CO2. Under an inverted fluorescence microscope, when a large number of cells in the virus control group showed fluorescence, while the cells in the cell control group remained fully grown and showed no fluorescence, the control system was considered fully qualified and ready for comprehensive observation. Similarly, the same experimental method was used to treat the fusion protein of porcine α and λ interferon with porcine ferritin. The results showed that binding to ferritin significantly enhanced the antiviral activity of interferon.
[0128] 1.8 Serum Drug Metabolism Analysis
[0129] Taking the Ferritin-IFN-γ fusion protein as an example, 18 healthy male rats weighing 180-220g were randomly divided into 3 groups. Each group was intravenously injected with a single dose (2.0mg / kg). -1 Ferritin-IFN-γ fusion protein or an equivalent amount of standard interferon-gamma was administered, with an untreated group serving as a control. Serum samples were collected at 0.5, 2.0, 4.0, 8.0, 12, 24, 48, 72, 96, 120, and 144 hours post-injection, and their anti-VSV-GFP activity was measured. In each treatment, the serum half-life of intravenously injected Ferritin-IFN-γ fusion protein was significantly prolonged compared to standard interferon-gamma. Furthermore, a prolonged serum drug metabolic half-life was also observed in experiments involving fusion proteins of porcine α- and λ-interferon with porcine ferritin.
[0130] 2. Experimental Results
[0131] 2.1 Western Result
[0132] The purified sample was identified by SDS-PAGE electrophoresis as a single band corresponding to the molecular weight, and Western blotting showed a reaction with the antibody, indicating that the purified protein was the designed target protein. Further mass spectrometry analysis showed that the obtained peptide values were largely consistent with the theoretical values, with a concordance rate exceeding 70%, further confirming that the purified protein was the target protein. The protein content of the purified protein was then determined, diluted to 1 mg / mL in tubes, and cryopreserved for subsequent experiments.
[0133] 2.2 Detection of antiviral activity of prokaryotic expression
[0134] The results of the antiviral activity assay are shown in Table 1 below. The per mg protein concentrations of IFN-γ were 512,000 IU, Ferritin-IFN-γ were 1,780,000 IU, PIFN-α were 465,000 IU, Ferritin-IFN-α were 1,580,000 IU, PIFN-λ were 446,000 IU, and Ferritin-IFN-λ were 1,512,000 IU. This indicates that the linkage between interferon and the ferritin heavy chain subunit can effectively enhance the antiviral activity of interferon. Figure 2 The image shows the green fluorescence of Ferritin-IFN-γ expressed in E. coli inhibiting VSV virus replication, and the various proportions of fluorescence observed after cells were infected with VSV-GFP, confirming the validity of interferon's ability to inhibit VSV-GFP infection.
[0135] Table 1. Detection of antiviral activity of IFN-γ and Ferritin-IFN-γ fusion protein
[0136]
[0137]
[0138] 2.3 Transmission electron microscopy and immunoelectron microscopy
[0139] Taking the Ferritin-IFN-γ fusion protein as an example, Figure 3 Transmission electron microscopy (TEM) and immunoelectron microscopy (IEM) observations of nanoparticles formed after denaturation and renaturation of Ferritin-IFN-γ expressed in *E. coli*. TEM reveals spherical structures with a diameter of approximately 20 nm, confirming successful renaturation of the target protein Fe-IFN-γ. The surrounding shadows represent surface-displayed interferon-gamma (see [link to TEM]). Figure 3 (A)). The primary antibody used in the immunogold labeling assay targeted ferritin. Immunoelectron microscopy revealed that the gold nanoparticles were primarily located at the core of the nanoparticles, strongly demonstrating that the nanoantibody was displayed on the ferritin surface in the form of a polymer (see [link]). Figure 3 (B)). Immunoelectron microscopy experiments using human hIFN-γ antibody as the primary antibody also observed the refolded sample, revealing that the gold label was present around the particles, further demonstrating that hIFN-γ is displayed on the surface of the nanoparticles (see [link]). Figure 3 (C)). Similarly, the fusion protein of porcine α and λ interferon with porcine ferritin also successfully demonstrated that interferon was displayed on the surface of nanoparticles.
[0140] 2.4 Serum Drug Metabolism Analysis
[0141] In vivo pharmacokinetic analysis in mice showed that the T1 / 2 value of the Ferritin-IFN-γ fusion protein was 23.81 hours (intravenous injection), which was 4.71 times longer than that of interferon-gamma (5.05 hours) (see...). Figure 4 The serum half-life of the Ferritin-IFN-γ fusion protein was significantly improved, and the concentration of IFN-γ in the untreated control group was much lower than that of the fusion protein with ferritin.
[0142] The T1 / 2 value of the fusion protein of porcine α-interferon and porcine ferritin was 16.12 hours, which was 5.3 times longer than that of α-interferon (3.03 hours). The T1 / 2 value of the fusion protein of porcine λ-interferon and porcine ferritin was 18.59 hours, which was 3.0 times longer than that of λ-interferon (6.19 hours). In summary, the serum drug metabolic half-life of the fusion proteins of the three types of interferon and their corresponding ferritins was significantly improved.
[0143] Experiment Example 3: Expression and Measurement of Fusion Proteins of Three Types of Interferon and Corresponding Ferritin in a Eukaryotic Expression System. Experiment 1. Experimental Methods
[0144] 1.1 Propagation of the silkworm nucleopolyhedrovirus parent strain BmBacmid and preparation of viral DNA
[0145] Prepare 1×TC-100 medium according to the AppliChem product instructions, adjust the pH to 6.22 with 2M NaOH, filter and sterilize the medium, add 10% fetal bovine serum, and culture silkworm cells BmN at 27°C. Infect approximately 50 mL of logarithmic growth phase cells with the parent strain of silkworm nucleopolyhedrovirus. After 3–4 days, collect the viral infection fluid, centrifuge at 10,000 rpm for 10 min, remove the precipitate, and centrifuge the supernatant at 25,000 rpm for 1 hour. Remove the supernatant again, and resuspend the viral particles in 1 mL of viral DNA extraction buffer (1 L contains 12.1 g Tris, 33.6 g EDTA, 14.1 g KCl, pH 7.5). Transfer the precipitate to a 1.5 mL centrifuge tube, add proteinase K to a final concentration of 50 μg / mL, incubate at 50 °C for 2 hours, then add 35% Sarkorsel to a final concentration of 1%, and continue incubating at 50 °C for 2 hours. Extract sequentially with equal volumes of saturated phenol, phenol:chloroform (1:1), and chloroform. Transfer the upper aqueous phase to a new tube, and add 1 / 10 volume of 3M chloroform. Add NaCl, then add 2 volumes of anhydrous ethanol, incubate at -20°C for at least 2 hours to precipitate viral DNA, centrifuge at 5000 rpm for 10 minutes, wash the precipitate once with 75% ethanol, and freeze-dry. Dissolve in 100 μL LTE Buffer and store at 4°C for later use.
[0146] 1.2 Construction of recombinant baculovirus rBmBacmid
[0147] Approximately 1×10 6 Cells at 15cm 2 After cells adhere to the culture flask, remove the culture medium containing fetal bovine serum (FBS), wash three times with FBS-free medium, and add 1.5 mL of FBS-free medium. Add 1 μg of baculovirus parental strain BmBacmid DNA (patent: ZL201110142492.4, publication number: CN102286534A), 2 μg of recombinant transfer plasmid, and 5 μL of liposomes to a sterile tube. Make up the volume to 60 μL with sterile double-distilled water, mix gently, and let stand for 15 min. Then, add the mixture dropwise to the culture flask for co-transfection. After culturing at 27℃ for 4 hours, 1.5 mL of serum-free medium and 300 μL of LFBS were added, and the cells were incubated at 27℃ for 4–5 days. The supernatant was collected for screening recombinant viruses rBmBacmid-IFN-γ, rBmBacmid-Ferritin-IFN-γ, rBmBacmid-PIFN-α, rBmBacmid-Ferritin-PIFN-α, rBmBacmid-PIFN-λ, and rBmBacmid-Ferritin-PIFN-λ. An appropriate amount of cells (approximately 70–80%) was seeded into 35 mm Petri dishes. After cell adhesion, the medium was aspirated, and the co-transfection supernatant was diluted to different concentrations. 1 mL of the co-transfection solution was added to the adherent cells and distributed evenly. After infection at 27°C for 1 hour, the infection fluid was aspirated. 2% low-melting-point agarose gel was melted in a 60°C water bath, cooled to 40°C, and mixed thoroughly with 2×TC-100 medium (containing 20% FBS) preheated to 40°C. 4 mL of gel was added to each petri dish, and after solidification, the dish was sealed with Parafilm. The dishes were incubated upside down at 27°C for 3–5 days and observed under a microscope. Selected samples were then purified, and the above steps were repeated for 2–3 rounds to obtain pure recombinant baculovirus.
[0148] 1.3 Amplification of recombinant virus rBmBacmid in silkworm cells
[0149] Normally growing BmN cells were infected with recombinant baculovirus rBmBacmid (PPH-IFN-γ, PPH-Ferritin-IFN-γ, PPH-PIFN-α, PPH-Ferritin-PIFN-α, PPH-PIFN-λ, PPH-Ferritin-PIFN-λ). After 3-5 days, when the cells clumped and shrank, the supernatant was collected to obtain a large amount of recombinant virus.
[0150] 1.4 Identification of Recombinant Viruses
[0151] PCR was used to analyze the integration of exogenous genes. The extraction method for cell-free viral genomic DNA was as follows: 150 μL of viral supernatant was added to 150 μL (0.5 mol / L) NaOH and mixed well. Then, 20 μL (8 mol / L) ammonium acetate was added and mixed well. The mixture was then extracted once with equal volumes of phenol and once with chloroform. After ethanol precipitation, the DNA was dissolved in 20 μL of TE buffer. 1 μL of the viral genomic DNA was used for PCR amplification. The reaction conditions were: 95℃, 30 s; 95℃, 15 s, 60℃, 15 s, 72℃, 60 s, for a total of 29 cycles; 72℃, 5 min. 15 μL of the reaction product was analyzed by electrophoresis, and the results confirmed the acquisition of recombinant virus. 1.5 Expression of recombinant virus in silkworms and silkworm pupae.
[0152] The silkworm pupae used were of the high-expression variety JY1 (preserved in the inventor's laboratory). JY1 silkworm rearing was conducted according to the standard methods described in *Chinese Sericulture* (Shanghai Science and Technology Press, 1991), edited by Lü Hongsheng. Forty-eight hours after feeding, silkworms of similar average weight and 15 pupae of similar average weight seven days after cocooning were selected. Each pupae and silkworm was inoculated with approximately 1.0 × 10⁻⁶ gram. 5 The concentration of recombinant protein expressed in silkworms was determined by ELISA using pfu rBmBacmid. Purified and quantified prokaryotic Ferritin-IFN-γ fusion protein was coated onto ELISA plates at different concentrations. Ultrapurified Fe-IFN-γ and negative control silkworm (Luc group) samples were diluted 5-fold (1:5 - 1:15625) and coated onto the ELISA plates respectively. A 1000-fold diluted rabbit human ferritin heavy chain monoclonal antibody was used as the primary antibody for 2 hours, and a 3000-fold diluted HRP-labeled goat anti-rabbit IgG antibody was used as the secondary antibody for 1 hour. A standard curve was plotted based on the absorbance at OD492 nm. After 4–5 days, diseased silkworm pupae and silkworm blood were collected and stored at -20℃ for ELISA detection. For the determination of interferon-gamma expression, the supernatant from high-speed centrifugation of hemolymph samples was used as the detection target, and a commercially available anti-human interferon-gamma antibody was used as the primary antibody. Other experimental procedures were the same as for the Fe-IFN-γ group.
[0153] Silkworm hemolymph was diluted with PBS and sonicated (10s × 10 times). Cell debris was removed by centrifugation at 12000 rpm for 10 minutes. The supernatant was then ultracentrifuged at 35000 rpm. The precipitate was resuspended in PBS. The supernatant was then ultracentrifuged at 35000 rpm for 3 hours. The precipitate was resuspended in PBS to obtain preliminarily purified ferritin nanoparticles displaying γ-interferon.
[0154] The concentration of recombinant protein expressed in silkworms was determined by ELISA. Ferritin-IFN-γ fusion protein expressed in prokaryotes was coated onto ELISA plates at different concentrations. Ultrapurified Fe-IFN-γ and negative control silkworm (Luc group) samples were diluted 5-fold (1:5-1:15625) and coated onto the ELISA plates respectively. A 1000-fold diluted rabbit human ferritin heavy chain monoclonal antibody was used as the primary antibody and incubated for 2 hours. A 3000-fold diluted HRP-labeled goat anti-rabbit IgG was used as the secondary antibody and incubated for 1 hour. A standard curve was plotted based on the absorbance at OD492 nm.
[0155] Similarly, the experimental procedures for the fusion proteins of porcine α and λ interferon with the corresponding ferritin were similar to those for the Fe-IFN-γ group.
[0156] 1.6 Western blotting detection
[0157] For specific operating procedures, please refer to Experimental Method 1.2. The expression level of interferon-gamma (γ-gamma) expressed in silkworms was determined using the supernatant from high-speed centrifugation of hemolymph samples after disruption, with a commercially available antibody against human γ-gamma as the primary antibody. Other experimental steps were the same as in the Fe-IFN-γ group. Similarly, the experimental procedures for the fusion proteins of porcine α- and λ-interferon with their corresponding ferritin were similar to those in the Fe-IFN-γ group.
[0158] 1.7 Electron Microscopy Observation
[0159] The purified sample was observed under an electron microscope. For specific experimental methods, please refer to the relevant steps in the aforementioned ionization experiment and Experiment Example 2.
[0160] 1.8 Detection of antiviral activity of fusion proteins of three types of interferon and corresponding ferritin expressed in a eukaryotic expression system
[0161] Taking interferon-gamma and ferritin-IFN-γ fusion protein as examples, the antiviral activity of interferon-gamma and ferritin-IFN-γ fusion protein expressed in the silkworm eukaryotic expression system was detected on the Vero / VSV*GFP system using the microcytopathic effect inhibition method. Healthy Vero cells were cultured at 3.0 × 10⁻⁶ cells / year. 5 The concentrated Ferritin-IFN-γ fusion protein and an equal volume of interferon-γ were seeded at a density of 100 μL / well in 96-well culture plates. Different dilutions of the concentrated Ferritin-IFN-γ fusion protein and interferon-γ were prepared using DMEM medium containing 70 mL / L fetal bovine serum. Each diluted sample was seeded at 100 μL / well into wells already confluent with VERO cells. At least 12 replicates were performed for each dilution and control protein solution. A cell control group without protein solution and VSV*GFP and a virus control group with VSV*GFP were also included. The cells were incubated at 37°C and 5% CO2 for 18–24 h. The culture was then diluted to 100 TCID50.50 VSV*GFP virus was added at 100 μL / well to culture wells after the supernatant had been aspirated, and incubated at 37°C and 5% CO2. Under an inverted fluorescence microscope, when a large number of cells in the virus control group showed fluorescence, while the cells in the cell control group remained fully grown and showed no fluorescence, the control system was considered fully qualified and ready for comprehensive observation. Similarly, the experimental procedures for the fusion proteins of porcine α and λ interferon with their corresponding ferritin were the same as those for the Fe-IFN-γ group.
[0162] 1.9 Serum Drug Metabolism Analysis
[0163] Thirty healthy male rats weighing 180-220g were randomly divided into 5 groups. Each group received an intravenous injection (1mg / kg). -1 Or a single oral gavage dose (5 mg / kg) -1 The Ferritin-IFN-γ fusion protein or interferon-γ expressed by the same expression system was used, with a control group of mice not treated with interferon. Serum samples were collected at 0.5, 2.0, 4.0, 8.0, 12, 24, 48, 72, 96, 120, and 144 h after injection, and their anti-VSV-GFP activity was measured. In each treatment, the serum half-life of the intravenously or orally administered Ferritin-IFN-γ fusion protein was significantly prolonged compared to interferon-γ. Similarly, the experimental procedures for the fusion proteins of porcine α and λ interferon with the corresponding ferritin were the same as those in the Fe-IFN-γ group; therefore, the serum half-life of the interferon-ferritin fusion protein was significantly prolonged compared to the corresponding allo-interferon.
[0164] 2. Experimental Results
[0165] 2.1 ELISA quantification and Western blotting results
[0166] The expression levels of Ferritin-IFN-γ, Ferritin-PIFN-α, and Ferritin-PIFN-λ in silkworm hemolymph were measured to be 712.113 μg / mL, 831.25 μg / mL, and 683.05 μg / mL, respectively, by ELISA. These levels and their antiviral activity were higher than those of the corresponding single-gene interferons used as controls. The purified samples were subjected to SDS-PAGE electrophoresis to identify characteristic bands with the corresponding molecular weights, and Western blotting confirmed that the purified protein was the designed and expressed target protein. Further mass spectrometry analysis showed that the obtained peptide values were largely consistent with theoretical values, further confirming that the purified protein was indeed the target protein. The protein content of the purified protein was then determined, diluted to 1 mg / mL in tubes, and cryopreserved for subsequent experiments.
[0167] 2.2 Results of antiviral activity assays for various eukaryotic expression products
[0168] Figure 5 The image shows the green fluorescence of the eukaryotic expression product Ferritin-IFN-γ inhibiting VSV viral replication. The antiviral activity results of each eukaryotic expression product are listed in Table 2. The antiviral activity assay showed that the Ferritin-IFN-γ fusion protein had significant antiviral activity, with a titer of 2.05 × 10⁻⁶. 7 At 0.5 mg / L, the potency of γ-interferon produced using the same expression system in previous patents and studies was only 5.5 million IU per 0.5 mg. Experiments demonstrated that the antiviral activity of interferon expressed in the eukaryotic expression system, and the antiviral activity of interferon and its corresponding ferritin fusion protein, were significantly higher than those in the prokaryotic expression system, showcasing the advantages of expressing natural silkworm proteins and indicating that the method of enhancing the antiviral activity of interferon using the silkworm system is effective. Simultaneously, the antiviral activity of the interferon and its corresponding ferritin fusion protein in the eukaryotic expression system was significantly greater than that of interferon alone, indicating that the fusion protein formed by the binding of interferon and ferritin has higher antiviral activity.
[0169] Table 2. Detection of antiviral activity of eukaryotically expressed interferon and corresponding ferritin fusion proteins.
[0170]
[0171] 2.3 Transmission electron microscopy and immunoelectron microscopy
[0172] Figure 6 The results of transmission electron microscopy and immunoelectron microscopy observations of eukaryotic expression of ferritin-interferon fusion protein; among them, Figure 6 (A) shows the results observed by transmission electron microscopy. Figure 6 (B) Immunoelectron microscopy with ferritin antibody as primary antibody: spherical material of the expected size can be observed, and gold particles of immunogold labeling with antiferritin heavy chain antibody as primary antibody can be seen attached to the core of the spherical material, indicating that the fusion protein is a spherical nanoparticle and displays IFN-γ on the surface of ferritin. Figure 6 (C) is an immunogold labeling image. Using human hIFN-γ antibody as the primary antibody, gold labeling particles can be observed around the spheres, further proving that hIFN-γ is displayed on the surface of the nanoparticles.
[0173] 2.4 Serum Drug Metabolism Analysis
[0174] Taking the Ferritin-IFN-γ fusion protein as an example, pharmacokinetic analysis in mice showed that, compared with interferon, the T1 / 2 value of the Ferritin-IFN-γ fusion protein was 27.66 hours (intravenous injection), which was 5.03 times longer than that of interferon-γ (5.50 hours) (see...). Figure 7(A)), the T1 / 2 value in the oral group was 32.78 hours (see [reference]). Figure 7 (B) The serum concentrations in the untreated control group were significantly lower than those of the fused ferritin at all time points. Similarly, the experimental procedures for the fusion proteins of porcine α and λ interferon with their corresponding ferritins were the same as those in the Fe-IFN-γ group. The T1 / 2 value of the Ferritin-PIFN-α fusion protein was 27.12 hours (intravenous injection), which was 8.9 times longer than that of α interferon (3.03 hours), and the T1 / 2 value of the Ferritin-PIFN-λ fusion protein was 28.56 hours (intravenous injection), which was 4.6 times longer than that of λ interferon (6.19 hours). The fusion proteins of interferon and their corresponding ferritins expressed by the eukaryotic expression system showed a better effect on prolonging the serum half-life. The T1 / 2 value of the oral Ferritin-PIFN-α fusion protein was 30.01 hours, and the T1 / 2 value of the Ferritin-PIFN-λ fusion protein was 31.38 hours, while the serum concentration in the untreated control group was close to zero. Compared with the corresponding interferon, the fusion protein of interferon and corresponding ferritin in the serum of mice in the oral administration group showed better antiviral activity. The fusion protein of interferon and corresponding ferritin showed the characteristics of low dosage and long-term effect when administered orally.
[0175] Experiment Example 4: Expression and Determination of Single Mutants of Three Interferons and Corresponding Ferritin Fusion Proteins in a Silkworm Eukaryotic Expression System
[0176] 1. Experimental Methods
[0177] 1.1 Construction of single-point mutant genes based on amino acid sequence
[0178] Based on the structure-activity theory of cytokines, mutations are performed at selected sites to improve potency. This invention uses the gene sequences of three interferons fused with their corresponding ferritin proteins as templates, designs multiple primer pairs to optimize the sequences, and performs site-directed mutagenesis. The site-directed mutagenesis is performed using fusion PCR, and a point mutation kit is used for the fusion PCR experiment.
[0179] Taking the Ferritin-IFN-γ fusion protein as an example, the amino acid sequence shown in SEQ ID NO.5 of the fusion protein was mutated using single point mutations as indicated by L189V, E202T, K227R, K236R, L249P, K261R, K273R, E286G, N290T, or K323R. The resulting mutant was named Ferritin-IFN-γ-M (L189V, E202T, K227R, K236R, L249P, K261R, K273R, E286G, N290T, K323R). This single mutant sequence was then expressed in a silkworm eukaryotic expression system. The experimental procedures for the porcine interferon fusion protein with the corresponding ferritin were the same.
[0180] 1.2 PCR amplification of single-point-mutated amino acid sequences of the fusion proteins of three interferons and their corresponding ferritin
[0181] 1.2.1 Primers required for single point mutation of Ferritin-IFN-γ:
[0182] Upstream and downstream primers on both sides:
[0183] F1: 5'-CGGGATCCGCCAACATGACCAGCCAAGTGCGTCAAA-3'
[0184] R1: 5'-CGGAATTCTCACTGAGAGGCCC-3'
[0185] intermediate upstream and downstream primers 1
[0187] F: 5'-TGGGATCT GTG GGATGTTACTGCCAGGACCCC-3'
[0188] R: 5'-ACATCC CAC AGATCCCAGCACGATGCACAGCT-3' 2
[0190] F: 5'-AGGCC ACG AACCTGAAAAAGTATTTCAATGCCG-3'
[0191] R: 5'-TTTTCAGGTT CGT GGCCTCTTTCACGTAGGGGT-3' 3
[0193] F: 5'-CATCCTG AGG AATTGGAAGGAAGAGTCCGATAG-3'
[0194] R: 5'-TCCAATT CCT CAGGATGCCCAGGAACAGGGTG-3' 4
[0196] F: 5'-CGATAGA AGG ATCATGCAGAGCCAAATCGTGT-3'
[0197] R: 5'-GCATGAT CCT TCTATCGGACTCTTCCTTCCAA-3' 5
[0199] F:5’-CTTCTACTTCAAG CCG TTTAAGAACTTCAAGGACGACCAG-3’
[0200] R:5’-A CGG CTTGAAGTAGAAGGACACGATTTGGCTC-3’ 6
[0202] F:5’-TATCCAG AGA AGCGTCGAGACAATCAAGGAAG-3’
[0203] R:5’-CGACGCT TCT CTGGATAGACTGGTCGTCCTTG-3’ 7
[0205] F:5’-GAACGTG AGG TTCTTCAACAGCAACAAGAAGAAA-3’
[0206] R:5’-TGAAGAA CCT CACGTTCATATCTTCCTTGATTGT-3’ 8
[0208] F:5’-TGACTTC GGG AAGCTCACAAACTACAGCGTGA-3’
[0209] R:5’-TGAGCTT CCC GAAGTCATCTCTTTTCTTCTTGTTG-3’ 9
[0211] F:5’-AGCTCACA ACC TACAGCGTGACCGACCTGAAC-3’
[0212] R:5’-GCTGTA GGT TGTGAGCTTCTCGAAGTCATCTC-3’ 10
[0214] F:5’-AAGACCGGCAAGAGA AGG CGGAGCCAGATGCTGTTT-3’
[0215] R:5’- CT TCTCTTGCCGGTCTTAGCAGCAGGGCTCAG-3’
[0216] 1.2.2 Primers required for unit point mutation of Ferritin-PIFN-α (only primers with preferential mutation are listed):
[0217] Upstream and downstream primers on both sides
[0218] F1: 5'-CGGGATCCGCCAACATGTGCAGCAGC-3'
[0219] R1: 5'-CGGAATTCTTATTCCTTCTTTCTGAGTCT-3'
[0220] intermediate upstream and downstream primers 1
[0222] F:5'-CCTTTCTCCTGC CCT GACCACCGTA-3'
[0223] R: 5'-TACGGTGGTC AGG GCAGGAGAAAG-3' 2
[0225] F: 5'-GTCCAG CGT GCGCAAGCTAT-3'
[0226] R: 5'-ATAGCTTGCGC ACG CTGGACTTG-3' 3
[0228] F: 5'-AAGCACC ACC CTGCAAGA-3'
[0229] R: 5'-TCTTGCAG GGT GGTGCTTGAAC-3'
[0230] 1.2.3 Primers required for single point mutation of Ferritin-PIFN-λ (only primers for preferential mutation are listed):
[0231] Upstream and downstream primers on both sides
[0232] F1: 5'-CGGGATCCGCCAACATGTGCAGCAGC-3'
[0233] R1: 5'-TTAAACACACAGGTCACCTGAAGC-3'
[0234] intermediate upstream and downstream primers 1
[0236] F: 5'-GGCTCAATTC AGA TCATTGTCT-3'
[0237] R: 5'-AGACAATGA TCT GAATTGAGCC-3' 2
[0239] F:5'-AGTGGCTCTG ACC GCCGAAGTTG-3'
[0240] R: 5'-AACTTCGGC GGT CAGAGCCACT-3' 3
[0242] F:5'-AAGAGGCAGA CCA CACCACTGGC-3'
[0243] R: 5'-GCCAGTGGTG TGG TCTGCCTCTT-3'
[0244] 1.3 Plasmid construction of single mutants of three interferons fused with their corresponding ferritin proteins
[0245] For specific experimental methods, please refer to Experiment Example 2.
[0246] 1.4 Transformation and identification of single mutants of recombinant plasmids containing three interferons and their corresponding ferritin fusion proteins
[0247] For specific experimental methods, please refer to Experiment Example 2.
[0248] 1.5 Construction and amplification of recombinant baculovirus rBmBacmid single mutant
[0249] For specific experimental methods, please refer to Example 3.
[0250] 1.6 Identification of recombinant viral single mutants
[0251] For specific experimental methods, please refer to Experiment Example 3.
[0252] 1.7 Expression of recombinant viral single mutants in silkworms and silkworm pupae
[0253] For specific experimental methods, please refer to Experiment Example 3.
[0254] 1.8 Detection of antiviral activity of three interferons and their corresponding ferritin fusion protein single mutants
[0255] For specific experimental methods, please refer to Experiment Example 3.
[0256] 2. Experimental Results
[0257] 2.1 Antiviral activity detection
[0258] The test results are listed in Table 3. Taking the Ferritin-IFN-γ fusion protein as an example, the titers of all Ferritin-IFN-γ fusion protein mutants were measured to be 4.83 × 10⁻⁶. 6 U / 0.5mg~5.58×10 7 U / 0.5mg, the antiviral activity was higher after mutations at four sites: E202T, L249P, K273R, and N290T, while the titer remained unchanged or even decreased after mutations at other sites. This indicates that the mutations at these four sites are effective and can improve the antiviral activity of Ferritin-IFN-γ. For Ferritin-PIFN-α fusion protein and Ferritin-PIFN-λ fusion protein, only mutants with improved antiviral activity after mutation are listed (mutants with no improvement or decrease in antiviral activity or titer compared to before mutation are not listed in the table).
[0259] Table 3. Detection results of antiviral activity of three interferons and their corresponding ferritin fusion proteins with single point mutations.
[0260]
[0261]
[0262] Note: Some poorly expressed and poorly active mutants were not mentioned in the article.
[0263] Experiment 5: Expression and Determination of Three Interferon-Corresponding Ferritin Fusion Protein Double Mutants in a Silkworm Eukaryotic Expression System
[0264] 1. Experimental Methods
[0265] 1.1 Construction of two-site mutant genes of amino acid sequences of three interferons and their corresponding ferritin fusion proteins
[0266] Taking the Ferritin-IFN-γ fusion protein as an example, this invention combines four preferred single point mutations (E202T, L249P, K273R, N290T) in pairs for double site mutation. The double site mutation is based on the single point mutation sequence, using Ferritin-IFN-γ as a template, and using the corresponding primers to perform fusion PCR.
[0267] There are a total of six combinations of two-site mutations: E202T-L249P, E202T-K273R, E202T-N290T, L249P-K273R, L249P-N290T, and K273R-N290T. The resulting mutants are named Ferritin-IFN-γ (E202T-L249P, E202T-K273R, E202T-N290T, L249P-K273R, L249P-N290T, and K273R-N290T).
[0268] The double-mutated coding sequence was amplified by PCR. The amplification primers are shown in Experiment 2. The experimental steps for porcine interferon and the corresponding ferritin were the same as above. The amplification primers are shown in Experiment 2. The above double-mutated sequence was expressed in the silkworm eukaryotic expression system.
[0269] 1.2 Construction of plasmids for double mutants of three interferons and their corresponding ferritin proteins
[0270] For specific experimental methods, please refer to Experiment Example 2.
[0271] 1.3 Transformation and Identification of Three Recombinant Plasmid Double Mutants
[0272] For specific experimental methods, please refer to Experiment Example 2.
[0273] 1.4 Construction and amplification of three recombinant baculovirus rBmBacmid double mutants
[0274] For specific experimental methods, please refer to Experiment Example 3.
[0275] 1.5 Identification of recombinant viral double mutants
[0276] For specific experimental methods, please refer to Experiment Example 3.
[0277] 1.6 Expression of recombinant viral double mutants in silkworms and silkworm pupae
[0278] For specific experimental methods, please refer to Experiment Example 3.
[0279] 1.7 Detection of antiviral activity of three interferons and their corresponding ferritin fusion protein double mutants
[0280] For specific experimental methods, please refer to Experiment Example 3.
[0281] 1.8 Serum drug metabolism analysis of three interferons and their corresponding ferritin fusion protein mutants
[0282] For specific experimental methods, please refer to Experiment Example 3.
[0283] 2. Experimental Results
[0284] 2.1 Antiviral activity detection
[0285] Taking the Ferritin-IFN-γ fusion protein as an example, the detection results are listed in Table 4. The titers of all Ferritin-IFN-γ fusion protein mutants were measured to be between 2.46 × 10⁻⁶. 7 U / 0.5mg~1.19×10 8 U / 0.5mg, the double mutations in the E202T-K273R and K273R-N290T groups resulted in higher titers of the expressed Ferritin-IFN-γ fusion protein compared to the original and single-mutated sequences. The titers of the other mutation sites remained unchanged or even decreased after mutation. This indicates that the mutations at these three sites are effective and can enhance the antiviral activity of the Ferritin-IFN-γ fusion protein mutants. For the Ferritin-PIFN-α and Ferritin-PIFN-λ fusion proteins, only mutants showing increased antiviral activity after mutation are listed (mutants without increased antiviral activity or titer compared to before mutation are not listed).
[0286] Table 4. Detection results of antiviral activity of three interferons and their corresponding ferritin fusion proteins with two-site mutations.
[0287]
[0288] Note: Some poorly expressed and poorly active double mutants were not included in the article.
[0289] 2.2 Serum drug metabolism analysis of mutants
[0290] The results are listed in Table 5, showing only the preferentially mutated strains. Compared to γ-interferon, the T1 / 2 value of the Ferritin-IFN-γ fusion protein double mutant E202T-K273R was 28.55 hours (intravenous injection), which was 5.19 times longer than that of interferon (5.50 hours). The T1 / 2 value of the oral group was 32.96 hours. The T1 / 2 value of the double mutant K273R-N290T was 29.12 hours (intravenous injection), and the T1 / 2 value of the oral group was 33.01 hours. Similarly, the experimental procedures for the fusion protein double mutants of porcine α and λ-interferon with the corresponding ferritin were the same as those for the Fe-IFN-γ group. The T1 / 2 value of the double mutant L223P-N350T of the Ferritin-PIFN-α fusion protein was 29.11 hours (intravenous injection), which was 9.61 times longer than that of α-interferon (3.03 hours), while the T1 / 2 value of the oral group was 31.09 hours. The T1 / 2 value of the double mutant K215R-L320P of the Ferritin-PIFN-λ fusion protein was 27.76 hours (intravenous injection), which was 4.49 times longer than that of λ-interferon (6.19 hours), while the T1 / 2 value of the oral group was 32.01 hours.
[0291] Table 5. Serum drug metabolism analysis of three interferons and their corresponding ferritin fusion protein mutants.
[0292]
Claims
1. A fusion protein, characterized in that, The fusion protein is obtained by linking the C-terminus of cytokines and monomeric ferritin subunits via a linker peptide, and the amino acid sequence of the fusion protein is shown in SEQ ID No.
11.
2. The gene encoding the fusion protein according to claim 1, characterized in that, The nucleotide sequence of the gene encoding the fusion protein is shown in SEQ ID No.
12.
3. A mutant of the fusion protein according to claim 1, characterized in that, The mutant is a mutant obtained by making a single point mutation of the amino acid shown in SEQ ID No. 11 according to any one of E202T, L249P, K273R or N290T; or a mutant obtained by making a double site mutation of E202T-K273R or K273R-N290T on the fusion protein shown in SEQ ID No.
11.
4. The coding gene of the mutant according to claim 3.
5. A recombinant expression vector or recombinant host cell containing the encoding gene of claim 4.
6. A method for preparing the fusion protein of claim 1 or the mutant of claim 3, characterized in that, include: (1) Construct a prokaryotic or eukaryotic expression vector for the encoding gene of the fusion protein or its mutant; (2) Transform the constructed prokaryotic or eukaryotic expression vector into the corresponding host cell, express the fusion protein in the host cell, purify and renature it to obtain the fusion protein.
7. The method according to claim 6, characterized in that, The coding gene of the fusion protein or its mutant is cloned into a baculovirus transfer vector to construct a recombinant transfer vector; the recombinant transfer vector is co-transfected with baculovirus DNA into insect cells to obtain recombinant baculovirus; the recombinant baculovirus is used to infect insect hosts or insect cells, and the infected insect hosts or insect cells are cultured to express the corresponding fusion protein, which is then purified to obtain the final product.
8. Use of the fusion protein of claim 1 or the mutant of claim 3 in the preparation of an anti-vesicular stomatitis virus drug.
9. Use of the encoding gene of claim 4, the recombinant expression vector of claim 5, or the recombinant host cell in the preparation of an anti-vesicular stomatitis virus drug.
Citation Information
Patent Citations
Insect bioreactors expressing multiple exogenous genes, their construction methods and applications
CN102286534A
SARS-CoV-2 neutralizing nano-antibody, self-assembled ferritin fusion nano-antibody, and preparation method and application of self-assembled ferritin fusion nano-antibody
CN114736293A
Fusion protein of Bst DNA polymerase and ferritin as well as mutant and application thereof
CN119320460A
Compositions and methods for modulating cytokines
CN119907687A
Grass carp gamma interferon fusion protein as well as mutant, coding gene and application thereof
CN120484093A
